Work

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

Year: 2011

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet

DOI: 10.1016/s0140-6736(11)60545-x

Authors: Roy S Herbst, Rafat Ansari, Frederique Bustin, Patrick Flynn, Lowell Hart, Gregory A Otterson, Gordana Vlahovic, Chang-Heok Soh, Paula O'Connor, John Hainsworth

Institutions: The University of Texas MD Anderson Cancer Center, Centre hospitalier régional de la Citadelle, Minnesota Oncology, Florida Cancer Specialists & Research Institute, The Ohio State University Wexner Medical Center, Duke Medical Center, Genentech, Sarah Cannon

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Genentech, University of Texas MD Anderson Cancer Center, National Cancer Institute

Awards: G1901027039, Cancer Center Support Grant, Cancer Center Support Grant

OpenAlex ID: W2155338842

FWCI: 33.95

Cites: 35

Cited by: 389

Related to: 10